PainReform Ltd
(NAS:PRFX)
$
2.92
-0.08 (-2.67%)
Market Cap: 1.77 Mil
Enterprise Value: -952,000.00
PE Ratio: 0
PB Ratio: 0
GF Score: 28/100 PainReform Ltd at Benzinga All Access Event (Virtual) Transcript
Dec 16, 2021 / 03:00PM GMT
Release Date Price:
$340.8
(-8.97%)
Spencer Israel
Benzinga - Media
Let's bring on Ilan Hadar right now, the CEO of PainReform. Mr. Hadar, how we doing today?
Ilan Hadar
PainReform Ltd. - CEO
I'm great, Spencer. Nice to meet you, and great to be here. How are you today?
Spencer Israel
Benzinga - Media
I'm doing fantastic. I feel like it should be Friday. It's not, but it's Friday in my head, and that's all that matters. So we'll start with this -- PainReform, tell us what you do, and then we'll go from there.
Ilan Hadar
PainReform Ltd. - CEO
PainReform is Israeli company founded back in 2008. We are doing our post-operative pain management drugs right now. We are working on our leading candidate to become post-operative pain management. It's PRF-110. It's a drug that's supposed to give relief of pain up to 72 hours post-operation.
Questions & Answers
Spencer Israel
Benzinga - Media
What is the unmet need here? Obviously there are many operations
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot